reports
Cidara Therapeutics to Participate in September Investor Conferences
Cidara Therapeutics to Participate in September Investor Conferences SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in the below September investor conferences. Details are as follows: Event: H.C. Wainwright 27th Annual Global Investment ConferenceDate: September 8, 2025Time: 4:00 PM ETFormat: Corporate Presentation Event: Morgan Stanley 23rd Annual Global Healthcare Conferen...
Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical ...
Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV’s 8th AVG and 3rd IMRP 2025 Meeting SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it will have two oral presentations, one of which is late-breaking, during the International Society for Respiratory Viruses (ISRV) 8th AntiViral Group (AVG) Meeting and 3rd International Meeting on Respiratory Pathogens (IMRP). The conferenc...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
PSTG PURE STORAGE INC. CLASS A
PAHC PHIBRO ANIMAL HEALTH CORPORATION CLASS A
NTAP NETAPP INC.
LPTH LIGHTPATH TECHNOLOGIES INC. CL A
A AGILENT TECHNOLOGIES INC.
AGX ARGAN INC.
ELF E.L.F. BEAUTY INC.
CHCI COMSTOCK HOLDING COMPANIES
RCMT RCM TECHNOLOGIES
STNE STONECO
CSTL CASTLE BIOSCIENCES
SOFI SOFI TECHNOLOGIES INC
IMRX IMMUNEERING CORP
DSGN DESIGN THERAPEUTICS INC
FTAI FORTRESS TRANSN & INFRAS INVS LLC
ASPI ASP ISOTOPES INC
FTREV FORTREA HOLDINGS INC.
KRRO KORRO BIO INC
RAPP RAPPORT THERAPEUTICS INC
ALMU AELUMA INC
RHLD RESOLUTE HOLDINGS MANAGEMENT INC
ASST ASSET ENTITIES INC
SNDK SANDISK CORP
INFU MULTI UNITS LU - AMUNDI US INFLATION EXPECTATIONS 10Y
Immuneering Announces Closing of $25 Million Private Placement
Immuneering Announces Closing of $25 Million Private Placement CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the closing of its previously announced private placement. The private placement was made to top-tier institutional and accredited investors, for total up front gross proceeds of approximately $25 million, before deducting fees and expenses. Immuneering sold: (i) an aggregate of 6,329,113 unregistered shares of the company’s Class A common stock...
Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate...
Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib - Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung cancer – CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced a clinical supply agreement with Eli Lilly and Company (NYSE:LLY) for its second-generation KRAS G12C inhibitor, olomorasib (LY3537982). The supp...
Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for I...
Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025 Webinar to be held on Wednesday, September 3, 2025 at 4:30 p.m. ET FOSTER CITY, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced it will host an investor educational webinar on TERN-701 in advance of the data re...
Immuneering Announces $25 Million Private Placement
Immuneering Announces $25 Million Private Placement CAMBRIDGE, Mass., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it has entered into a definitive securities purchase agreement for a private placement of securities to top-tier institutional and other accredited investors, that is expected to result in up front gross proceeds to the Company of approximately $25 million, before deducting fees and expenses. The closing of the private placement is subject to customary...
Immuneering Reports Second Quarter 2025 Financial Results and Provides...
Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates - Company now plans to share updated OS and PFS data from first-line pancreatic cancer patients (N = 34) treated with atebimetinib + mGnP in Q3 2025, earlier than prior guidance - - Exceptional 94% overall survival (OS) observed at 6 months in ongoing Phase 2a trial of atebimetinib plus modified Gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients (N = 34) - - Newly issued U.S. composition of matter patent for atebimetinib expected to provide exclusivity into 2042, with subseq...
- Jonathan Moreland
TLYS TILLYS
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
RGEN REPLIGEN CORPORATION
PENN PENN NATIONAL GAMING INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
LLY ELI LILLY AND COMPANY
HRTX HERON THERAPEUTICS INC
CHD CHURCH & DWIGHT CO. INC.
CBZ CBIZ INC.
AKAM AKAMAI TECHNOLOGIES INC.
ASA ASA
CC CHEMOURS CO.
SSSS SUTTER ROCK CAPITAL CORP.
LFST LIFESTANCE HEALTH GROUP
ENVX INC.
BRBR ENOVIX CORP
GRNT BELLRING BRANDS INC
SMRT GRANITE RIDGE RESOURCES INC
MNR SMARTRENT INC
NBBK MACH NATURAL RESOURCES LP
NB BANCORP INC.
Cidara Therapeutics Provides Corporate Update and Reports Second Quart...
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results Phase 2b NAVIGATE clinical trial evaluating CD388 for the prevention of seasonal influenza met primary and all secondary efficacy endpoints for all dose groupsEnd of Phase 2 meeting request submitted to the U.S. Food and Drug Administration (FDA)Closed upsized public offering for gross proceeds of $402.5 million; significantly strengthened balance sheet to conduct planned Phase 3 program for CD388Added to Russell 2000® and Russell 3000® IndexesConference call and webcast today at 5:00 PM Eastern ...
Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results an...
Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates Phase 1 trial of TERN-701 in chronic myeloid leukemia (CML) enrolling well; efficacy and safety data including 6-month major molecular response (MMR) rates expected in 4Q25 Phase 2 trial of TERN-601 for obesity completed enrollment; 12-week efficacy, safety and tolerability data expected in early 4Q25 Cash runway into 2028 focused on advancing CML program internally and partnering metabolic assets Terns to host a TERN-701-focused educational webinar in September 2025 FOSTER CITY,...
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under...
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) FOSTER CITY, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of August 1, 2025 equity inducement awards to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were app...
- Jonathan Moreland
MERC MERCER INTERNATIONAL INC.
CDXS CODEXIS
PETS PETMED EXPRESS INC.
CLRB CELLECTAR BIOSCIENCES
NHF NEXPOINT CREDIT STRATEGIES FUN
CZWI CITIZENS COMMUNITY BANCORP
LOOP LOOP INDUSTRIES
CHMG CHEMUNG FINANCIAL CORP.
FVCB FVCBANKCORP
FGBI FIRST GUARANTY BANCSHARES
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
CMTV COMMUNITY BANCORP INC. VT
DMAC DIAMEDICA THERAPEUTICS INC.
CRDF CARDIFF ONCOLOGY INC
IMRX IMMUNEERING CORP
NSPR INSPIREMD INC
BRCC BRC INC
LEXX LEXARIA BIOSCIENCE CORP
PMNT PERFECT MOMENT LTD.
DMA DESTRA MULTI ALTERNATIVE FUND
NYC NEW YORK CITY REIT
GF INC.
FGEN THE NEW GERMANY FUND
CCIF INC.
CVM FIBROGEN INC.
CARLYLE CREDIT INCOME FUND
CEL-SCI CORPORATION
- Jonathan Moreland
- Jonathan Moreland
SIGI SELECTIVE INSURANCE GROUP INC.
SFNC SIMMONS FIRST NATIONAL CORPORATION CLASS A
RLI RLI CORP.
PRGS PROGRESS SOFTWARE CORPORATION
ORCL ORACLE CORPORATION
NG. NOVAGOLD RESOURCES INC.
MERC MERCER INTERNATIONAL INC.
HELE HELEN OF TROY LIMITED
WELL WELLTOWER INC.
CTAS CINTAS CORPORATION
CIVB CIVISTA BANCSHARES
MEDP MEDPACE HOLDINGS INC.
DYN DYNEGY INC.
PETS PETMED EXPRESS INC.
PBT PERMIAN BASIN ROYALTY TRUST
LIND LINDBLAD EXPEDITIONS HOLDINGS
KYN KAYNE ANDERSON MLP INVESTMENT CO.
CRSP CRISPR THERAPEUTICS AG
CRVL CORVEL CORP.
CLRB CELLECTAR BIOSCIENCES
ELTP ELITE PHARMACEUTICALS INC
COGT COGINT
BWB INC.
PGC BRIDGEWATER BANCSHARES
LOOP PEAPACK-GLADSTONE FINANCIAL CORP.
CHMG LOOP INDUSTRIES
A2JHXF CHEMUNG FINANCIAL CORP.
FVCB CEVA LOGISTICS AG
FGBI FVCBANKCORP
REZI FIRST GUARANTY BANCSHARES
GRX RESIDEO TECHNOLOGIES
PCB INC.
FRHC THE GABELLI HEALTHCARE & WELLNESSRX TRUST
CMTV PACIFIC CITY FINANCIAL CORP
KYMR FREEDOM HOLDING CORP
DMAC COMMUNITY BANCORP INC. VT
NSPR KYMERA THERAPEUTICS
BRCC DIAMEDICA THERAPEUTICS INC.
BPRN INSPIREMD INC
STRW BRC INC
PMNT BANK OF PRINCETON
NYC STRAWBERRY FIELDS REIT INC.
GF PERFECT MOMENT LTD.
LION NEW YORK CITY REIT
FGEN INC.
BMNR THE NEW GERMANY FUND
NEGG INC.
LIONSGATE STUDIOS CORP
FIBROGEN INC.
BITMINE IMMERSION TECHNOLOGIES INC.
NEWEGG COMMERCE INC.
Cidara Therapeutics to Report Second Quarter 2025 Financial Results an...
Cidara Therapeutics to Report Second Quarter 2025 Financial Results and Host Quarterly Conference Call on August 7, 2025 SAN DIEGO, July 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that it will report its second quarter 2025 financial results and operational highlights after the close of the U.S. financial markets on Thursday, August 7, 2025. The Company will host a conference call and webcast at 5:00 PM Eastern Time to discuss t...
- Jonathan Moreland
PSEC PROSPECT CAPITAL CORPORATION
ORCL ORACLE CORPORATION
NG. NOVAGOLD RESOURCES INC.
MERC MERCER INTERNATIONAL INC.
HELE HELEN OF TROY LIMITED
WELL WELLTOWER INC.
CEVA CEVA INC.
CDTX CIDARA THERAPEUTICS
CIVB CIVISTA BANCSHARES
NXRT NEXPOINT RESIDENTIAL TRUST INC.
DYN DYNEGY INC.
GIII G-III APPAREL GROUP LTD.
PETS PETMED EXPRESS INC.
THO THOR INDUSTRIES INC.
GRF EAGLE CAPITAL GROWTH FUND INC
CRSP CRISPR THERAPEUTICS AG
CRVL CORVEL CORP.
CLRB CELLECTAR BIOSCIENCES
ELTP ELITE PHARMACEUTICALS INC
COGT COGINT
BWB INC.
DOMO BRIDGEWATER BANCSHARES
FGBI DOMO INCORPORATED
PVH FIRST GUARANTY BANCSHARES
GRX PHILLIPS-VAN HEUSEN CORPORATION
INLX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
FRHC INTELLINETICS
CMTV INC.
RZLT FREEDOM HOLDING CORP
KYMR COMMUNITY BANCORP INC. VT
BTBT REZOLUTE
TERN INC.
CTO KYMERA THERAPEUTICS
VERA BIT DIGITAL (N SHARES)
IMRX TERNS PHARMACEUTICALS
BRCC CONSOLIDATED-TOMOKA LAND CO
BPRN VERA THERAPEUTICS INC
PMNT IMMUNEERING CORP
NYC BRC INC
ACTU BANK OF PRINCETON
MBRX PERFECT MOMENT LTD.
LION NEW YORK CITY REIT
THAR INC.
FGEN ACTUATE THERAPEUTICS INC.
CCIF MOLECULIN BIOTECH INC.
BMNR LIONSGATE STUDIOS CORP
NEGG THARIMMUNE INC.
FIBROGEN INC.
CARLYLE CREDIT INCOME FUND
BITMINE IMMERSION TECHNOLOGIES INC.
NEWEGG COMMERCE INC.
Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After ...
Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas - Announces Completion of Phase 1 Study of Elraglusib in Pediatric Patients - Prolonged and Durable Complete Responses (CRs) Observed in Two of Ten Refractory Ewing Sarcoma Patients - Two Additional Patients Had Durable Stable Disease in Notoriously Difficult-to-Treat Cancer - Confirmed Partial Response (PR) in a patient with a desmoplastic small-round-cell tumor (DSRCT) - Company Initiating Planning of...
- Jonathan Moreland
VAC MARRIOTT VACATIONS WORLDWIDE CORPORATION
PSEC PROSPECT CAPITAL CORPORATION
ORCL ORACLE CORPORATION
NG. NOVAGOLD RESOURCES INC.
MERC MERCER INTERNATIONAL INC.
WELL WELLTOWER INC.
CEVA CEVA INC.
CDTX CIDARA THERAPEUTICS
PZG PARAMOUNT GOLD NEVADA CORP.
NXRT NEXPOINT RESIDENTIAL TRUST INC.
GIII G-III APPAREL GROUP LTD.
OXM OXFORD INDUSTRIES INC.
THO THOR INDUSTRIES INC.
GRF EAGLE CAPITAL GROWTH FUND INC
CRVL CORVEL CORP.
SVRA SAVARA
CLRB CELLECTAR BIOSCIENCES
ELTP ELITE PHARMACEUTICALS INC
RSSS RESEARCH SOLUTIONS
BWB BRIDGEWATER BANCSHARES
DOMO DOMO INCORPORATED
FGBI FIRST GUARANTY BANCSHARES
PVH PHILLIPS-VAN HEUSEN CORPORATION
AMPY AMPLIFY ENERGY
INLX INTELLINETICS
FRHC INC.
CMTV FREEDOM HOLDING CORP
RZLT COMMUNITY BANCORP INC. VT
KYMR REZOLUTE
WSC INC.
BTBT KYMERA THERAPEUTICS
TERN WILLSCOT MOBILE MINI HOLDINGS CORP
NUVB BIT DIGITAL (N SHARES)
CTO TERNS PHARMACEUTICALS
VERA NUVATION BIO INC (A)
IMRX CONSOLIDATED-TOMOKA LAND CO
XLO VERA THERAPEUTICS INC
SSBK IMMUNEERING CORP
PMNT XILIO THERAPEUTICS INC
NYC SOUTHERN STATES BANCSHARES INC
ACTU PERFECT MOMENT LTD.
SUNS NEW YORK CITY REIT
MBRX INC.
LION ACTUATE THERAPEUTICS INC.
HYMC SUNRISE REALTY TRUST
THAR MOLECULIN BIOTECH INC.
FGEN LIONSGATE STUDIOS CORP
CCIF HYCROFT MINING HOLDING CORPORATION
BTCS THARIMMUNE INC.
FIBROGEN INC.
CARLYLE CREDIT INCOME FUND
TOUCHIT TECHNOLOGIES
- Jonathan Moreland
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.